Personalized medicine in lung cancer: what we need to know
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要Lung cancer is a complex and often fatal disease. The recent discovery of activating mutations in EGFR and fusion genes involving ALK has set the stage for personalized medicine for lung cancer. Patients selected using biomarkers have benefited from the development of EGFR tyrosine kinase inhibitors and ALK inhibitors with considerable improvement in tumor control and survival. Four key areas of knowledge that are essential to the development of targeted therapy are discussed in this Review: knowing the target, knowing the biomarker, knowing the end point and knowing the mechanisms of resistance.
著者Mok TSK
期刊名稱Nature Reviews Clinical Oncology
出版年份2011
月份11
日期1
卷號8
期次11
出版社Nature Publishing Group
頁次661 - 668
國際標準期刊號1759-4774
電子國際標準期刊號1759-4782
語言英式英語
Web of Science 學科類別Oncology; ONCOLOGY

上次更新時間 2020-24-11 於 00:20